UK Approved The Use Of Remdesivir To Treat Some COVID 19 Patients .pdf
Original filename: UK Approved The Use Of Remdesivir To Treat Some COVID-19 Patients.pdf
This PDF 1.7 document has been generated by WPS 文字 / , and has been sent on pdf-archive.com on 04/06/2020 at 05:25, from IP address 103.121.x.x.
The current document download page has been viewed 27 times.
File size: 90 KB (2 pages).
Privacy: public file
Download original PDF file
UK Approved The Use Of Remdesivir To
Treat Some COVID-19 Patients
Recently, the Department of Health and Social Care of UK announced that the
antiviral drug Remdesivir will be used for patients with COVID-19 that meet
certain clinical standards to help them recover.
Clinical trials for Remdesivir are being carried out in the UK and globally. Early
data shows that the drug can shorten the recovery time of patients by about 4
The opinion of the Early access to medicines scheme (EAMS) and Medicines and
the Healthcare products Regulatory Agency (MHRA) supports the treatment of
Remdesivir for NHS patients who meet specific clinical conditions. At present,
due to the limited supply of Remdesivir, only a part of patients who are likely to
achieve the greatest benefit will be treated by priority.
Lord Bethell, British Minister of Innovation, said: "This is a huge progress we
have made. In this unprecedented period, we must be at the forefront of
medical development while always putting patient safety first. We make
decisions with the latest, professional scientific advice at the heart and will
continue to monitor the success of clinical trials across the country to ensure the
best results for patients in the UK."
Remdesivir is a nucleotide analogue under study with broad-spectrum antiviral
activity, which has shown efficacy in a variety of emerging viral pathogens
including Ebola Viruses, Marburg virus, Middle East respiratory syndrome
(MERS) and SARS. An in vitro test conducted by Gilead showed that Remdesivir
is active against SARS-CoV-2. Several ongoing phase III clinical trials are
evaluating the safety and efficacy of Remdesivir in the treatment of COVID-19.
How does it work?
Remdesivir is a member of the most important class of drugs (called nucleoside
analogs). Currently, there are more than 30 of these drugs have been approved
for the treatment of viruses, parasites, cancer and bacterial infections.
The drug works by stopping or interrupting virus replication, thereby preventing
the virus from multiplying and infecting more cells in the body. In the case of
coronavirus infection, the drug works by blocking RNA polymerase, which is one
of the vital enzymes required for viruses to replicate their genetic material and
reproduce in the body.
Huateng Pharma, a leading intermediates manufacturers in China, is
exclusively focusing on manufacturing API's Intermediates, such as Baloxavir
Marboxil intermediates, Remdesivir
intermediates, Favipiravir intermediates, Semaglutide intermediates and so
on. We are able to provide the production of these intermediates for
research use with capacities varying from gram to kilograms with high purity
to our customers all over the world.
Reference: This article is based on an English Press Release issued by the Department of
Health and Social Care of UK on 26 May.